AVN-944
DRACPC ID DRACPC0062
Active Ingredients AVN-944
Description An orally available, synthetic small molecule with potential antineoplastic activity. AVN944 inhibits inosine monosphosphate dehydrogenase (IMPDH), an enzyme involved in the de novo synthesis of guanosine triphosphate (GTP), a purine molecule required for DNA and RNA synthesis. Inhibition of IMPDH deprives cancer cells of GTP, resulting in disruption of DNA and RNA synthesis, inhibition of cell proliferation, and the induction of apoptosis. AVN944 appears to have a selective effect on cancer cells in that deprivation of GTP in normal cells results in a temporary slowing of cell growth only. IMPDH is overexpressed in some cancer cells, particularly in hematological malignancies.
Synonyms AVN944; AVN 944; Inosine Monophosphate Dehydrogenase Inhibitor AVN944; AVN-944
Type Biotech
Disease Leukemia, Lymphoma, Multiple myeloma, Pancreatic cancer
Classification
IMPDH inhibitor Peptide and derivative
Structure Information
Molecular Formula C25H27N5O5
Molecular Weight 477.5
Active Sequence Not available
Sequence Length Not available
Modification Not available
IUPAC Name [(2R)-1-cyanobutan-2-yl] N-[(1S)-1-[3-[[3-methoxy-4-(1,3-oxazol-5-yl)phenyl]carbamoylamino]phenyl]ethyl]carbamate
InChI InChI=1S/C25H27N5O5/c1-4-20(10-11-26)35-25(32)28-16(2)17-6-5-7-18(12-17)29-24(31)30-19-8-9-21(22(13-19)33-3)23-14-27-15-34-23/h5-9,12-16,20H,4,10H2,1-3H3,(H,28,32)(H2,29,30,31)/t16-,20+/m0/s1
InChI_Key GYCPCOJTCINIFZ-OXJNMPFZSA-N
SMILES CC[C@@H](OC(N[C@H](C1=CC=CC(NC(NC2=CC(OC)=C(C=C2)C3=CN=CO3)=O)=C1)C)=O)CC#N
External Codes
PubChem CID 9918559
DrugBank Accession Number DB05500
NCI Thesaurus Code C49181
UNII I3NPL1V48Q GSRS
CAS 297730-17-7
Drug approval
Drug indication
Investigated for use/treatment in cancer/tumors (unspecified), leukemia (unspecified), lymphoma (unspecified), multiple myeloma, and pancreatic cancer.
The drug is not approved.
| ClinicalTrials.gov Identifier | Title | Condition or disease | Phase | Purpose |
|---|---|---|---|---|
| NCT00273936 | A Phase I Trial of AVN-944 in Patients With Advanced Hematologic Malignancies | Acute Leukemia; Chronic Leukemia; Multiple Myeloma; Hodgkin's Lymphoma; Non-Hodgkin's Lymphoma; Waldenstrom's Macroglobulinemia | Phase 1 | Treatment |
| NCT00923728 | A Phase 1 Trial of AVN944, an IMPDH Inhibitor, in Adults With Advanced Stage Solid Tumors | Refractory Solid Tumors | Not Applicable | Treatment |
| NCT00493441 | A Phase II Study of AVN944 in Combination With Gemcitabine for the Treatment of Pancreatic Cancer | Pancreatic Cancer | Phase 2 | Treatment |
More clinical information is obtained from ClinicalTrials.gov.
